# Program Announcement

Department of Defense Congressionally Directed Medical Research Programs

Tuberous Sclerosis Complex Research Program

Exploration – Hypothesis Development Award

Funding Opportunity Number: W81XWH-10-TSCRP-EHDA

## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Funding Opportunity Description</td>
<td>2</td>
</tr>
<tr>
<td>A. Program Description</td>
<td>2</td>
</tr>
<tr>
<td>B. FY10 TSCRP Mission and Focus Areas</td>
<td>2</td>
</tr>
<tr>
<td>C. Award Description</td>
<td>2</td>
</tr>
<tr>
<td>D. Eligibility</td>
<td>3</td>
</tr>
<tr>
<td>E. Funding</td>
<td>3</td>
</tr>
<tr>
<td>F. Award Administration</td>
<td>4</td>
</tr>
<tr>
<td>II. Timeline for Submission and Review</td>
<td>4</td>
</tr>
<tr>
<td>III. Submission Process</td>
<td>4</td>
</tr>
<tr>
<td>A. Step 1 – Pre-Application Components</td>
<td>4</td>
</tr>
<tr>
<td>B. Step 2 – Application Components</td>
<td>5</td>
</tr>
<tr>
<td>IV. Information for Application Review</td>
<td>8</td>
</tr>
<tr>
<td>A. Application Review and Selection Overview</td>
<td>8</td>
</tr>
<tr>
<td>B. Review Criteria</td>
<td>9</td>
</tr>
<tr>
<td>V. Administrative Actions</td>
<td>10</td>
</tr>
<tr>
<td>VI. Contact Information</td>
<td>12</td>
</tr>
<tr>
<td>VII. Application Submission Checklist</td>
<td>13</td>
</tr>
</tbody>
</table>
I. FUNDING OPPORTUNITY DESCRIPTION

A. Program Description

The Tuberous Sclerosis Complex Research Program (TSCRP) was established in fiscal year 2002 (FY02) to promote innovative research focused on decreasing the clinical impact of tuberous sclerosis complex (TSC). Appropriations for the TSCRP from FY02 through FY09 totaled $23.5 million (M). The FY10 appropriation is $6M.

B. FY10 TSCRP Mission and Focus Areas

The mission of the TSCRP is to encourage innovative research aimed at understanding the pathogenesis of TSC, and to translate these findings to the care of individuals with TSC. Within this context, the TSCRP encourages applications to the FY10 program that address these vital program focus areas:

- TSC-related cognitive and developmental studies.
- Innovative studies historically underrepresented in TSC research to include: ○ TSC management in adults
  o Skin involvement
  o Individualized prognosis
  o Epigenetic factors (with prognosis and variability issue)
  o Cardiac involvement (lesions that spontaneously resolve), and
  o Metabolic and nutritional effects.

TSCRP Research Resources Initiative: Resources developed through TSCRP-funding that are available to the scientific community can be found at http://cdmrp.army.mil/tscrp/tscresources. Investigators are urged to leverage and contribute to these resources, and include a sharing and distribution plan in the proposal. Refer to the General Application Instructions, Appendix 4, for more information.

C. Award Description

The TSCRP Exploration – Hypothesis Development Award (EHDA) mechanism was first offered in FY09. Since that time, 24 EHDA applications have been received, and 4 have been recommended for funding.

The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in tuberous sclerosis complex research. Results of studies conducted through this award should provide the scientific rationale upon which a new hypothesis can be based, or these results should provide initial principles of an innovative hypothesis. This award is designed to provide investigators with the opportunity to pursue serendipitous observations. The presentation of preliminary data is encouraged, but not required.
It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the project’s innovation and the potential impact on TSC.

Because these awards are designed for preliminary investigations, projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110). Additional information on the protection of human subjects and exempt or expedited review status may be found at https://www.bids.tswg.gov/TSWG/bids.nsf/5DD5E2BA50F02C18852572B1005F5B8B/$file/Title_32_CFR_Part_219.pdf. Applications proposing studies that do not qualify for exempt or expedited review status will be administratively withdrawn. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Research Award mechanism.

D. Eligibility

PIs at all academic levels (or equivalent) are eligible to submit applications. Refer to the General Application Instructions, Appendix 1, for general eligibility information.

E. Funding

- The maximum period of performance is 2 years.
- The maximum allowable funding for the entire period of performance is $100,000 in direct costs.
- The applicant may request the entire maximum direct cost amount for a project that may be less than the maximum 2-year period of performance.
- Regardless of the period of performance proposed, the applicant may not exceed the maximum direct cost. In addition to the direct costs, indirect costs may be proposed in accordance with the organization’s negotiated rate agreement.

Within the guidelines provided in the General Application Instructions, funds can cover:

- Salary
- Research supplies
- Equipment
- Travel between collaborating organizations
- Travel costs of up to $1,800 per year to attend scientific/technical meetings
- Other direct costs as described in the General Application Instructions for the Detailed Budget and Justification

The Office of the Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately $0.9M of the $6M FY10 TSCRP appropriation to fund approximately six EHDA Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of Federal funds for this program.
F. Award Administration

No changes in institution will be allowed once the application has been funded. Awards will be made approximately 4 to 6 months after receiving a funding notification letter, but no later than September 30, 2011. Refer to the General Application Instructions, Appendix 4, for general award administration information.

II. TIMELINE FOR SUBMISSION AND REVIEW

- Pre-application Submission Deadline: 5:00 p.m. Eastern time (ET), April 29, 2010
- Application Submission Deadline: 11:59 p.m. ET, May 20, 2010
- Scientific Peer Review: June 2010
- Programmatic Review: August 2010

*Application submissions will not be accepted unless the pre-application process is completed by the pre-application deadline.*

III. SUBMISSION PROCESS

Submission is a two-step process requiring both (1) pre-application submission through the CDMRP eReceipt system (https://cdmrp.org/) and (2) application submission through Grants.gov (http://www.grants.gov/).

Submission of the same research project to different funding opportunities within the same program and fiscal year is discouraged. The Government reserves the right to reject duplicative applications.

PIs and organizations identified in the application should be the same as those identified in the pre-application. If a change in PI or organization is necessary after submission of the pre-application, the PI must contact the eReceipt help desk at help@cdmrp.org or 301-682-5507.

A. Step 1 – Pre-Application Components

All pre-application components must be submitted through the CDMRP eReceipt system by 5:00 p.m. ET on the deadline.

The pre-application consists of the following components, which are organized in the CDMRP eReceipt system by separate tabs (Refer to the General Application Instructions for additional information on pre-application submission.):

- Proposal Information – Tab 1
- Proposal Contacts – Tab 2
- Collaborators and Conflicts of Interest – Tab 3
- Required Files – Tab 4
**Letter of Intent (LOI) Narrative (one-page limit):** Provide a brief description of the research to be conducted. LOI Narratives are used for program planning purposes only (e.g., reviewer recruitment) and will not be reviewed during either the peer or programmatic review sessions.

- Submit Pre-application – Tab 5
- Other Documents Tab
  Not applicable.

**B. Step 2 – Application Components**

Applications are submitted by the Authorized Organizational Representative (AOR) through Grants.gov (http://www.grants.gov/). Applications must be submitted by **11:59 p.m. ET on the deadline.**

Each application submission must include the completed application package of forms and attachments identified in Grants.gov for this Program Announcement/Funding Opportunity.

The Grants.gov application package consists of the following components (Refer to the General Application Instructions, Section II.B., for additional information on application submission):

1. **SF 424 (R&R) Application for Federal Assistance Form:** Refer to the General Application Instructions, Section II.B., for detailed information.

2. **Attachments Form**
   - **Attachment 1: Project Narrative (four-page limit):** Upload as “ProjectNarrative.pdf.”
     
     Describe the proposed project in detail using the outline below. The presentation of preliminary data is encouraged, but not required.
     
     - **Background:** Present the ideas and reasoning behind the proposed work. Cite relevant literature. Describe previous experience most pertinent to this project.
     - **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.
     - **Specific Aims:** Concisely explain the project’s specific aims to be funded by this application. If this proposed work is part of a larger study, present only tasks that the DOD award would fund.
     - **Research Strategy:** Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail for analysis. Address potential problem areas and present alternative methods and approaches. **This award may not be used to conduct clinical trials or studies that are not exempt under 32 CFR 219.101(b) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110).**
• **Attachment 2: Supporting Documentation.** Start each document on a new page. Combine and upload as a single file named “Support.pdf.” If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. **Each component has no page limit unless otherwise noted.**
  - References Cited: List all relevant references using a standard reference format that includes the full citation (i.e., author(s), year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate). The inclusion of Internet URLs to references is encouraged.
  - List of Acronyms and Symbols: Provide a list of acronyms and symbols (e.g., PCR = polymerase chain reaction).
  - Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the US Army Medical Research and Materiel Command (USAMRMC). Indicate if Government-owned facilities or equipment are proposed for use. Reference should be made to the original or present contract under which the facilities or equipment items are now accountable. There is no form for this information.
  - Publications and/or Patent Abstracts (five-document limit): Include relevant publication URLs and/or patent abstracts. If publications are not publicly available, then they must be included. Extra items will not be reviewed.
  - Letters of Organizational Support: Provide a letter (or letters if applicable), signed by the Department Chair or appropriate organization official, reflecting the laboratory space, equipment, and other resources available for the project.
  - Letters of Collaboration (if applicable) (two-page limit per letter): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the resources necessary for the proposed work.
  - Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.
  - Provide plans for sharing of data and research resources (if applicable).

• **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf.”
  - Background: Present the ideas and reasoning behind the proposed work.
  - Objective/Hypothesis: State the objective/hypothesis to be tested. Provide evidence or rationale that supports the objective/hypothesis.
  - Specific Aims: State the specific aims of the study.
  - Study Design: Briefly describe the study design including appropriate controls.
o Innovation: Briefly describe how the proposed project uses innovation to advance the detection, diagnosis, and/or treatment of tuberous sclerosis complex.

o Impact: Briefly describe how the proposed project will have an impact on tuberous sclerosis complex research or patient care.

**Attachment 4: Public Abstract (one-page limit):** Upload as “PublicAbs.pdf.”

o Clearly describe, in a manner readily understood by lay persons, the rationale and objective for the proposed work.

o Do not duplicate the technical abstract.

o Describe the ultimate applicability of the research.
  - What types of patients will it help, and how will it help them?
  - What are the potential clinical applications, benefits, and risks?
  - What is the projected time it may take to achieve a patient-related outcome?

o If the research is too basic for clinical applicability, describe the interim outcomes.

o What are the likely contributions of this study to advancing the field of research?

**Attachment 5: Statement of Work (SOW) (three-page limit):** Upload as “SOW.pdf.” Refer to the General Application Instructions, Section II.B., for detailed information.

**Attachment 6: Detailed Budget and Justification (no page limit):** Upload as “Budget.pdf.” Use the Detailed Budget and Justification form (available for download on the Full Announcement page in Grants.gov). Refer to the General Application Instructions, Section II.B., for detailed information.

**Attachment 7: Subaward Detailed Budget and Justification (if applicable) (no page limit):** Use a separate Detailed Budget and Justification form for each subaward budget. Combine into a single file and upload as “SubBudgets.pdf.” Refer to the General Application Instructions, Section II.B., for detailed information.

**Attachment 8: Impact Statement (one-page limit):** Upload as “Impact.pdf.” Explain how the expected results of the study will make an original and important contribution to the goal of advancing TSC research and its impact on patient care. Describe the potential clinical applications, benefits, and risks. The Impact Statement will be available for both peer review and programmatic review.

**Attachment 9: Innovation Statement (one-page limit):** Upload as “Innovation.pdf.” Summarize how the proposed work is innovative. Describe how the proposed project uses innovation to advance the detection, diagnosis, and/or treatment of tuberous sclerosis complex. Investigating the next logical step or incremental advancement on published data is not considered innovative.
Although not all-inclusive, the following examples are ways in which the proposed work may be innovative, and are intended to help PIs frame the innovative features:

- Study concept – Investigation of a novel idea and/or research question.
- Research method or technology – Use of novel research methods or new technologies, including technology development, to address a research question.
- Novel method or technology – Development of a novel method or technology for preventing, detecting, diagnosing, or treatment.
- Existing methods or technologies – Application or adaptation of existing methods or technologies for novel research or clinical purposes, or for research or clinical purposes that differ fundamentally from those originally intended.

The Innovation Statement will be available for both peer review and programmatic review.

3. **Research & Related Senior/Key Person Profile (Expanded) Form:** Refer to the General Application Instructions, Section II.B., for detailed information.

   - PI Biographical Sketch (four-page limit): Upload as “Biosketch_LastName.pdf.”
   - PI Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”
   - Key Personnel Biographical Sketches (four-page limit each): Upload as “Biosketch_LastName.pdf.”
   - Key Personnel Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

4. **Project/Performance Site Location(s) Form:** Refer to the General Application Instructions, Section II.B., for detailed information.

---

**IV. INFORMATION FOR APPLICATION REVIEW**

**A. Application Review and Selection Overview**

All applications are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is a scientific peer review of applications against established criteria for determining scientific merit. The second tier is a programmatic review that compares applications to each other and makes recommendations for funding to the Commanding General, USAMRMC, based on scientific merit, the overall goals of the program, and specific intent of the award mechanism. The highest scoring applications from the first tier of review are not automatically recommended for funding. Additional information about the two-tier review process used by the CDMRP may be found at [http://cdmrp.army.mil/fundingprocess](http://cdmrp.army.mil/fundingprocess)

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Each level of review requires panelists to sign a nondisclosure statement attesting that application and evaluation information will not be disclosed outside the panel. Violations of the non-disclosure statement can result in the
dissolving of a panel(s) and other corrective actions. Organizational personnel and PIs are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panelists or PIs that compromise the confidentiality of the review process may also result in suspension or debarment of their employing organizations from Federal awards. Furthermore, it is a crime for Federal officials to disclose confidential information of one party to another third party (Title 18 United States Code 1905).

B. Review Criteria

1. Peer Review: All applications will be evaluated according to the following criteria, which are listed in decreasing order of importance.

   - **Innovation**
     - How the proposed research is innovative in one or more of the following ways: Concept or question, research methods or technologies, adaptations of existing methods or technologies, or other ways.
     - How the project proposes new paradigms or challenges existing paradigms.
     - How the proposed research represents more than an incremental advance upon published data.

   - **Impact**
     - How the application addresses a critical problem in tuberous sclerosis complex research or patient care.
     - How the project makes an original and important contribution to the goal of advancing research on the treatment of tuberous sclerosis complex or on the quality of life of patients.

   - **Research Strategy and Feasibility (preliminary data encouraged but not required)**
     - How the scientific rationale supports the project and its feasibility as demonstrated by a critical review and analysis of the literature and logical reasoning.
     - How well the hypotheses or objectives, aims, experimental design, methods, and analyses are developed.
     - How well the PI acknowledges potential problems and addresses alternative approaches.
     - How the intended results should give rise to a testable hypothesis.

The following will not be individually scored, but may impact the overall evaluation of the application:
• **Personnel**
  ○ The PI’s potential for contributing to the tuberous sclerosis complex research field.
  ○ How the PI’s record of accomplishment demonstrates his/her ability to accomplish the proposed work.
  ○ Appropriateness of the levels of effort for successful conduct of the proposed work.

• **Environment**
  ○ How the scientific environment is appropriate for the proposed research.
  ○ How the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).
  ○ How the quality and extent of institutional support are appropriate for the proposed research.

• **Budget**
  ○ Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement/Funding Opportunity.

• **Application Presentation**
  ○ How the writing and components of the application influenced the review.

2. **Programmatic Review:** The following equally weighted criteria are used by programmatic reviewers to make funding recommendations.

  • Ratings and evaluations of the peer reviewers
  • Programmatic relevance
  • Relative innovation and impact
  • Program portfolio composition
  • Adherence to the intent of the award mechanism

V. **ADMINISTRATIVE ACTIONS**

After receipt of pre-applications from CDMRP eReceipt or applications from Grants.gov, the following administrative actions may occur:

A. **Rejection**

The following will result in administrative rejection of the application:

  • Project Narrative exceeds page limit.
  • Project Narrative is missing.
  • Budget is missing.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- Pre-application is not submitted.

**B. Modifications**

- Pages exceeding the specified limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.
- Following the application deadline, you may be contacted by CDMRP via email with a request to provide certain missing supporting documents (excluding those listed in Section V-A, Rejection). The missing documents must be provided by 5:00 p.m. ET on the second full business day following the date the email was sent. Otherwise, the application will be reviewed as submitted.

**C. Withdrawal**

The following may result in administrative withdrawal of the application:

- FY10 TSCRP Integration Panel (IP) member(s) is found to be involved in the preapplication or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting document. A list of the FY10 TSCRP IP members may be found at [http://cdmrp.army.mil/tscrp/panel10](http://cdmrp.army.mil/tscrp/panel10)
- Submission of the same research project to different funding opportunities within the same program and fiscal year.
- The application does not conform to this Program Announcement/Funding Opportunity description to an extent that precludes appropriate review.
- Direct costs as shown on the detailed budget form exceed maximum allowed by this Program Announcement/Funding Opportunity.
- Inclusion of URLs with the exception of links to published references.
- Studies not exempt under 32 CFR 219.101(b) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110).

**D. Withhold**

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending institutional investigation. The institution will be requested to provide the findings of the investigation to the US Army Medical Research Acquisition Activity (USAMRAA) Contracting/Grants Officer for a determination of the final disposition of the application.
VI. CONTACT INFORMATION

A. CDMRP Program Announcement Help Desk: Questions related to Program Announcement/Funding Opportunity content or submission requirements should be directed to the CDMRP Program Announcement help desk, which is available Monday through Friday from 7:30 a.m. to 4:00 p.m. ET. Submit questions as early as possible. Response times will vary depending upon the volume of inquiries. Every effort will be made to answer questions within 5 working days.

   Phone: 301-619-7079
   Email: cdmrp.pa@amedd.army.mil

B. CDMRP eReceipt System Help Desk: Questions related to the submission of the pre-application through the eReceipt system should be directed to the CDMRP eReceipt system help desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET.

   Phone: 301-682-5507
   Email: help@cdmrp.org

C. Grants.gov Contact Center: Questions related to application submission through the Grants.gov portal should be directed to Grants.gov help desk, which is available 24 hours a day, 7 days a week. Please note that the CDMRP Program Announcement and eReceipt system help desks are unable to provide technical assistance regarding Grants.gov submissions.

   Phone: 800-518-4726
   Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement/Funding Opportunity. If the application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.
## VII. APPLICATION SUBMISSION CHECKLIST

<table>
<thead>
<tr>
<th>Grants.gov Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SF-424 (R&amp;R) Application for Federal Assistance Form</strong></td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td><strong>Attachments Form</strong></td>
<td>Upload Project Narrative (ProjectNarrative.pdf) as Attachment 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Supporting Documentation (Support.pdf) as Attachment 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Technical Abstract (TechAbs.pdf) as Attachment 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Public Abstract (PublicAbs.pdf) as Attachment 4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Statement of Work (SOW.pdf) as Attachment 5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Detailed Budget and Justification (Budget.pdf) as Attachment 6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Subaward Detailed Budget and Justification (SubBudgets.pdf) as Attachment 7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Impact statement (Impact.pdf) as Attachment 8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Innovation statement (Innovation.pdf) as Attachment 9</td>
<td></td>
</tr>
<tr>
<td><strong>Research &amp; Related Senior/Key Person Profile (Expanded)</strong></td>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach PI Current &amp; Pending Support (Support_LastName.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Current &amp; Pending Support (Support_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
</tr>
<tr>
<td><strong>Project/Performance Site Location(s) Form</strong></td>
<td>Complete form as instructed</td>
<td></td>
</tr>
</tbody>
</table>